Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Musette

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Frontiers in Immunology|July 18, 2022
Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 PatientsGérôme Bohelay, Marina Alexandre, Christelle Le Roux-Villet, et al.
The New England Journal of Medicine|August 10, 2007
A single cycle of rituximab for the treatment of severe pemphigusPascal Joly, Hugo Mouquet, Jean-Claude Roujeau, et al.
Frontiers in Medicine|November 24, 2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific ConferenceJinmin Lee, Victoria P Werth, Russell P Hall, et al.
Chemical Research in Toxicology|November 3, 2016
New Approaches to Investigate Drug-Induced HypersensitivityMonday O Ogese, Shaheda Ahmed, Ana Alferivic, et al.
Immunity|March 31, 2019
A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGFα-Mediated Recruitment of NeutrophilsBaptiste Janela, Amit A Patel, Mai Chan Lau, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Frontiers in Immunology|July 18, 2022
Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 PatientsGérôme Bohelay, Marina Alexandre, Christelle Le Roux-Villet, et al.
The New England Journal of Medicine|August 10, 2007
A single cycle of rituximab for the treatment of severe pemphigusPascal Joly, Hugo Mouquet, Jean-Claude Roujeau, et al.
Frontiers in Medicine|November 24, 2018
Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific ConferenceJinmin Lee, Victoria P Werth, Russell P Hall, et al.
Chemical Research in Toxicology|November 3, 2016
New Approaches to Investigate Drug-Induced HypersensitivityMonday O Ogese, Shaheda Ahmed, Ana Alferivic, et al.
Immunity|March 31, 2019
A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGFα-Mediated Recruitment of NeutrophilsBaptiste Janela, Amit A Patel, Mai Chan Lau, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Pageof 5